Medical Program: Combination to Combat: Second Line Therapy Options for NSCLC

Combination to Combat: Second Line Therapy Options for NSCLC

Combination to Combat: Second Line Therapy Options for NSCLC
RestartResume
In an evolving therapeutic landscape, chemoimmunotherapy is becoming the standard of care. But could we be leaving our patients with fewer options?
  • Overview

    Chemoimmunotherapy has become more prevalent as a first-line treatment option for patients with non-small cell lung cancer (NSCLC). However, by compressing two therapies into one, we could be left with fewer alternatives if patients progress. Dr. Howard Jack West exposes these potential challenges and offers his perspective on second-line approaches in NSCLC care.

    Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Facebook Comments

NEW FEATURES:

Register

Join the Global Oncology Academy of learners.
Registration is free and easy.

Register Now